BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Metabolism of xenobiotics
,
Ischemia
,
Heart
,
Holistic medicine
,
Lipopolysaccharide
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
TCRzeta
(gene)
Summary
General Info
Body Atlas
Most Correlated Tissues
T Lymphocyte (regulatory) of peripheral blood
T Lymphocyte (CD4+) of peripheral blood
Natural killer cell of peripheral blood
T Lymphocyte (CD8+) of peripheral blood
Mononuclear cell of peripheral blood
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Loading...
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
Loading...
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
Loading...
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
Loading...
Explore Curated Studies Results
Literature
Most Relevant Literature
Advances in CD247.
CD3D and CD247 are the molecular targets of septic shock.
Integration of ζ-deficient CARs into the CD3-zeta gene conveys potent cytotoxicity in T and NK cells…
CD247, a Potential T Cell-Derived Disease Severity and Prognostic Biomarker in Patients With Idiopat…
FYN and CD247: Key Genes for Septic Shock Based on Bioinformatics and Meta-Analysis.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer
PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastat…
Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas
CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML
CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ